Detección de Reacciones Adversas a Medicamentos y Errores de Medicación en pacientes internados en el Servicio de la Unidad Coronaria de un hospital provincial

BRUNA FUNES, FLORENCIA NOEL; SIERRA, PATRICIA; OLIVERA, MARÍA EUGENIA; ROMAÑUK, CAROLINA BEATRIZ

Rosario-Santa Fe

Congreso; 4ta Reunión Internacional de Ciencias Farmacéuticas-RICiFa 2016; 2016

RICIFA

Patient safety is a priority of the health system worldwide, due to that health care can cause serious risks to patients. The risks can be classified as "preventable" (medication errors, MEs) and "non-preventable" (adverse drug reactions, ADRs). Early detection of such risks is essential to improve patient safety. The aim of this study was to analyze inpatients drug prescriptions for obtaining information regarding the use of drugs in the Coronary Care Unit (CCU), in order to determine the incidence of ADRs and identify MEs.This work was developed in the Pharmacovigilance Unit of Hospital Córdoba. An observational, descriptive and prospective study of drug prescriptions in the CCU during May 2016 was carried out. Two thousand and two hundred and sixteen prescriptions of 83 different drugs from 23 patients were validated. The MEs were classified according to the National Coordinating Council for MEs Reporting and Prevention and current national regulations. The severity of MEs was determined according to the categories adopted by the International Federation of Pharmacy. To assess the causality of ADRs, the algorithm Karch-Lasagna was used.An amount of 1753 MEs were detected in 63 of the 83 prescription medications. The most common MEs were: drug dose omission (35.8%), use of abbreviations (33.3%), trade name prescription (15.0%), and omission of both administration route (13.5%) and frequency (2.6%). Of all drugs, 28 were high alert medication and in 26 of them at least one error was found. All MEs detected were classified as "harmless errors" (category B).Three suspected ADRs in 3 patients who were prescribed bismuth cream or lactulose/ vaseline were found. In both cases, sucralfate and piperacillin/tazobactam were classified as "possible" responsible of diarrhea or constipation.